Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL155558 | 0.95 | ACHE (0.50) | ACHEEPHX1MGLLBCHE | |
| Formaldehyde SCHEMBL19181447 | 0.92 | ACHE (0.47) | ACHEEPHX1MGLLBCHE | |
| Acetic Acid SCHEMBL27577998 | 0.91 | ACHE (0.46) | ACHEEPHX1MGLLBCHE | |
| Carbamic Acid SCHEMBL28326378 | 0.89 | ACHE (0.45) | ACHEEPHX1MGLLBCHE | |
| SCHEMBL28237222 | 0.87 | ACHE (0.42) | ACHEEPHX1MGLLBCHE | |
| SCHEMBL28857977 | 0.85 | BCHE (0.37) | ACHEEPHX1MGLLBCHE | |
| Phenoxyethanol SCHEMBL16538205 | 0.83 | RECQL (0.48) | ACHE | |
| SCHEMBL29445404 | 0.80 | ACHE (0.37) | ACHEEPHX1MGLL | |
| SCHEMBL30253440 | 0.79 | ACHE (0.36) | ACHEEPHX1MGLL | |
| Oxazolidine SCHEMBL5854392 | 0.79 | ACHE (0.36) | ACHEEPHX1MGLLBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170007517-A1 | Cosmetic Compositions Comprising Cyanodiphenylacrylates | ELC MAN LLC (US) | 2017-01-12 | — | — | US | disclosed |
| US-20090035240-A1 | Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent | ELC MANAGEMENT LLC | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170007517-A1 | Cosmetic Compositions Comprising Cyanodiphenylacrylates | DCLRE1A, CUTA, RAD23B | ACHE 1011/4885EPHX1 1281/4885MGLL 65/4885 |
| US-20090035240-A1 | Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent | SMARCC1, RARG, RARA | ACHE 2962/4885EPHX1 3123/4885MGLL 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.